Literature DB >> 33155564

Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series.

Evrim Şirin1, Ahmet Hamdi Akgülle1, Osman Mert Topkar1, Ömer Sofulu1, Said Erkam Baykan1, Bülent Erol1.   

Abstract

OBJECTIVE: The aim of this study was to present the mid-term functional outcomes and recurrence rate in patients with giant cell tumor of bone (GCTB) treated by intralesional extended curettage, electrocauterization, and polymethylmethacrylate (PMMA) cementation.
METHODS: In this retrospective observational study, 79 consecutive patients (41 females, 38 males; mean age=39 years; age range=19-62 years) who were diagnosed and treated for GCTB between 2005 and 2017 were identified from hospital medical records. All patients were treated by intralesional extended curettage using high-speed burr, electrocauterization of the cavity, and filling the defect with PMMA. No additional local adjuvants were used. The mean follow-up period was 47 months (range=24-96). The tumors were graded according to the radiological classification system described by Campanacci. Functional outcomes were evaluated using the Musculoskeletal Tumor Society Score (MSTS) preoperatively, one year postoperatively, and at the final follow-up. Postoperative complications and recurrence rates were recorded.
RESULTS: Twenty-nine tumors were located in the distal femur, 23 in the proximal tibia, nine in the distal radius, five in the proximal humerus, five in the pelvis, three in the proximal fibula, two in the distal ulna, two in the distal tibia, and one in the second metatarsal. According to Campanacci classification, 37 tumors were grade III, 32 grade II, and 10 grade I. The mean MSTS score was 46.1% (range 40.2 to 71.4%) preoperatively, 91.7% (range 73.3% to 100%) one year postoperatively, and 86.3 % (range 66.2% to 96,1%) at the final follow-up. The overall complication rate was 7.6%; which included local tumor recurrence in four patients, superficial wound infection in one, and deep wound infection in another. The recurrence rate was 5.1% (4 patients). Recurrent tumors were located at the distal femur in three patients and proximal tibia in one.
CONCLUSION: With satisfactory functional results and low recurrence rates at the mid-term follow-up, GCTB can be treated effectively with intralesional extended curettage, electrocauterization, and PMMA cementation. LEVEL OF EVIDENCE: Level IV, Therapeutic study.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33155564      PMCID: PMC7646609          DOI: 10.5152/j.aott.2020.19082

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  43 in total

1.  Thermal necrosis induced by electrocauterization as a local adjuvant therapy in local aggressive bone tumors, what is the safe limit for surgical margins? An experimental study.

Authors:  Murat Aydin; Kerem Basarir; Mehmet Armangil; Huseyin Yusuf Yildiz; Yener Saglik; Hasan Bilgili; Nihat Yumusak
Journal:  Arch Orthop Trauma Surg       Date:  2015-06-29       Impact factor: 3.067

2.  Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor.

Authors:  Pietro Ruggieri; Andreas F Mavrogenis; Giuseppe Ussia; Andrea Angelini; Panayiotis J Papagelopoulos; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

3.  Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution.

Authors:  Xiaohui Niu; Qing Zhang; Lin Hao; Yi Ding; Yuan Li; Hairong Xu; Weifeng Liu
Journal:  J Bone Joint Surg Am       Date:  2012-03-07       Impact factor: 5.284

4.  Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.

Authors:  Manish G Agarwal; Manit K Gundavda; Rajat Gupta; Rajeev Reddy
Journal:  Clin Orthop Relat Res       Date:  2018-09       Impact factor: 4.176

5.  Recurrent giant cell tumor of long bones: analysis of surgical management.

Authors:  Frank M Klenke; Doris E Wenger; Carrie Y Inwards; Peter S Rose; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2010-09-16       Impact factor: 4.176

6.  High-Speed Burring with and without the Use of Surgical Adjuvants in the Intralesional Management of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis.

Authors:  H Algawahmed; Robert Turcotte; F Farrokhyar; M Ghert
Journal:  Sarcoma       Date:  2010-07-27

7.  Long bones giant cells tumors: treatment by curretage and cavity filling cementation.

Authors:  N Fraquet; G Faizon; P Rosset; J -M Phillipeau; D Waast; F Gouin
Journal:  Orthop Traumatol Surg Res       Date:  2009-09-19       Impact factor: 2.256

8.  Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance.

Authors:  Jing Zhang; Jian Dong; Zuozhang Yang; Xiang Ma; Jinlei Zhang; Mei Li; Yun Chen; Yingying Ding; Kun Li; Zhiping Zhang
Journal:  World J Surg Oncol       Date:  2015-05-01       Impact factor: 2.754

9.  Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence.

Authors:  Georg W Omlor; Jessica Lange; Marcus Streit; Simone Gantz; Christian Merle; Thomas Germann; Gunhild Mechtersheimer; Jörg Fellenberg; Burkhard Lehner
Journal:  World J Surg Oncol       Date:  2019-04-23       Impact factor: 2.754

10.  Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.

Authors:  Shinji Tsukamoto; Yuu Tanaka; Andreas F Mavrogenis; Akira Kido; Masahiko Kawaguchi; Costantino Errani
Journal:  Clin Orthop Relat Res       Date:  2020-05       Impact factor: 4.755

View more
  1 in total

1.  Comparative Analysis of Two Surgical Treatment Options for Giant Cell Tumor of the Proximal Femur: Extended Curettage and Segmental Resection.

Authors:  Yuhao Yuan; Qing Liu; Yupeng Liu; Ziyi Wu; Wei Zhong; Hongbo He; Wei Luo
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.